Learn About New MS Treatment Options

Understanding Multiple Sclerosis and Treatment Evolution

Multiple sclerosis (MS) is a condition where the immune system mistakenly attacks the protective covering of nerve fibers in the brain and spinal cord. This damage disrupts communication between the brain and the rest of the body, leading to symptoms like fatigue, mobility challenges, vision problems, and cognitive difficulties. The condition affects approximately 2.3 million people worldwide, with about 1 million living in the United States.

MS treatment has changed dramatically over the past two decades. In the 1990s, only a handful of disease-modifying therapies existed, and many people with MS had limited options for slowing disease progression. Today, the landscape looks entirely different. Doctors now have more than 20 disease-modifying treatments available, offering patients and their healthcare teams many choices to explore.

The goal of modern MS treatment is to reduce how often relapses occur and slow the progression of disability. Different treatment types work in different ways—some calm down the overall immune system, while others target specific immune cells that attack nerve tissue. Some treatments are taken by mouth daily, others by injection weekly or monthly, and still others given by infusion in a medical setting.

Understanding what treatment options exist helps people with MS have informed conversations with their neurologists. Treatment decisions depend on many factors, including the type of MS someone has, how active the disease appears, other health conditions, lifestyle preferences, and how well previous treatments have worked.

Practical Takeaway: Learning about different MS treatment categories and how they function provides a foundation for discussing options with healthcare providers and understanding why certain treatments might be recommended.

Injectable Disease-Modifying Therapies

Injectable treatments represent some of the earliest disease-modifying therapies developed for MS and remain important options today. These medications are administered under the skin (subcutaneously) or into muscle (intramuscularly) and work by modulating immune system activity to reduce inflammation in the central nervous system.

Interferon beta medications are among the most established injectable options. Interferon beta-1a can be given as an intramuscular injection once weekly or a subcutaneous injection three times weekly. Interferon beta-1b is given as a subcutaneous injection every other day. These medications have been used for more than 25 years and have demonstrated ability to reduce relapse rates by approximately 30% in relapsing-remitting MS. They work by enhancing the immune system's regulatory functions and reducing inflammatory responses.

Glatiramer acetate is another injectable option administered as a daily subcutaneous injection or as a three-times-weekly injection depending on the formulation. This medication is thought to work by creating immune tolerance to myelin proteins, essentially training the immune system to stop attacking nerve coverings. Clinical trials showed it reduced relapse rates by about 29% compared to placebo in people with relapsing-remitting MS.

The mitoxantrone category includes a medication delivered by intravenous infusion every three months. This is typically reserved for more aggressive forms of MS because of potential long-term side effects, but it can be effective at slowing progression in secondary progressive MS and aggressive relapsing-remitting disease.

Injection site reactions are common with subcutaneous medications and may include redness, itching, or induration at the injection site. Some people experience flu-like symptoms, particularly with interferon medications, though these often decrease over time. These side effects are generally manageable and reversible.

Practical Takeaway: Injectable therapies offer established safety profiles with decades of real-world use, making them valuable reference points when evaluating newer treatment options.

Oral Medications for MS Management

The development of oral disease-modifying therapies transformed MS treatment by offering patients a simpler administration method than injections. Several oral medications are now available, each with different mechanisms of action and varying intensity of immune suppression.

Fingolimod was the first oral disease-modifying therapy approved for MS. It works by trapping immune cells in lymph nodes, preventing them from reaching the central nervous system. Clinical trials showed fingolimod reduced relapse rates by approximately 54% compared to placebo in people with relapsing-remitting MS. This medication requires initial monitoring because it can temporarily slow heart rate and affect blood pressure when first started.

Teriflunomide is an oral medication taken daily that inhibits immune cell proliferation. Studies demonstrated about 31% reduction in relapse rates compared to placebo. Because this medication stays in the system for an extended period, people taking it need regular blood work to monitor liver and blood cell function.

Dimethyl fumarate is an oral medication taken twice daily that works through multiple mechanisms, including reducing inflammatory responses in the nervous system. Clinical trials showed approximately 53% reduction in relapse rates. Common side effects include flushing and stomach upset, which often improve over time.

Cladribine is an oral medication taken in short pulses—typically five days per month for two consecutive months per year. It depletes certain types of lymphocytes and has shown strong efficacy in clinical trials, with sustained reduction in relapse rates. Because of its immunosuppressive effects, regular monitoring is needed.

Siponimod is a newer oral medication that selectively affects certain immune cells. It has demonstrated effectiveness in secondary progressive MS, a form where disease progression occurs more gradually without clear relapses. Clinical trials showed it slowed progression by approximately 26% compared to placebo.

Practical Takeaway: Oral medications offer convenience and vary in dosing schedules and monitoring requirements, helping individuals choose options that fit their lifestyle and medical situation.

Infusion-Based and Monoclonal Antibody Treatments

Infusion-based treatments represent the most intensive category of disease-modifying therapies and are often considered when other treatments haven't provided adequate disease control. These medications are delivered intravenously, usually at a medical facility, and work by targeting specific immune cells or molecules involved in MS disease processes.

Natalizumab is a monoclonal antibody that blocks a molecule allowing immune cells to cross the blood-brain barrier. This prevents inflammatory cells from entering the central nervous system. Clinical trials showed natalizumab reduced relapse rates by approximately 68% compared to placebo—among the highest efficacy rates of any MS treatment. However, natalizumab carries a risk of progressive multifocal leukoencephalopathy (PML), a serious brain infection, particularly in people with certain viral markers. This risk requires careful patient monitoring and selection.

Ocrelizumab is a monoclonal antibody targeting B cells, immune cells that play a central role in MS. Clinical trials demonstrated approximately 46% reduction in relapse rates for relapsing-remitting MS and the first drug to show slowing of progression in primary progressive MS (where progression occurs from disease onset without distinct relapses). Ocrelizumab is given as an infusion twice yearly.

Alemtuzumab is an intravenous infusion given as two annual courses, each consisting of infusions over five days. This medication depletes lymphocytes and then allows immune reconstitution. Clinical trials showed approximately 55% reduction in relapse rates compared to interferon beta. Because alemtuzumab causes profound immune suppression, careful monitoring for secondary autoimmune conditions is necessary.

Rituximab, while originally developed for cancer treatment, has shown effectiveness in MS and is sometimes used as an off-label treatment. It targets B cells similarly to ocrelizumab and is given as intravenous infusions.

Infusion treatments generally require pre-medication to prevent reactions and monitoring during and after administration. Most people tolerate these medications well, though infusion reactions can occur. These treatments often require the most intensive medical supervision but offer strong disease control for people with active disease.

Practical Takeaway: Infusion-based therapies offer high efficacy for active disease but require careful medical monitoring and facility-based administration, making them suitable when disease activity remains high despite other treatments.

Newer and Emerging Treatment Approaches

MS treatment continues to evolve, with pharmaceutical research exploring new mechanisms and patient populations. Understanding emerging options provides context for discussions with neurologists about what might become available in the coming years.

S1P receptor modulators represent a newer category with several medications in this class beyond fingolimod. Ozanimod